Skip Navigation

European Heart Journal 2003 24(3):266-273; doi:10.1016/S0195-668X(02)00202-6
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Radke, P.W
Right arrow Articles by Sigwart, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radke, P.W
Right arrow Articles by Sigwart, U
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Outcome after treatment of coronary in-stent restenosis

Results from a systematic review using meta-analysis techniques

P.W Radkea,b,*, A Kaisera,b, C Frostc and U Sigwarta

a Royal Brompton & Harefield NHS Trust, London, UK
b Department of Cardiology, RWTH University Hospital Aachen, Aachen, Germany
c London School of Hygiene and Tropical Medicine, Medical Statistics Unit, London, UK

Received December 19, 2001; accepted February 27, 2002 * Corresponding author. Department of Cardiology, RWTH University Hospital, Pauwelsstrasse 30. D-52057 Aachen, Germany

u.sigwart{at}rbh.nthames.nhs.uk

Aims To evaluate the clinical outcome after treatment of coronary in-stent restenosis.

Methods and results For identification of the relevant literature a specific search strategy was conducted and explicit inclusion criteria were defined to avoid selection bias. Based on the selected literature, a systematic review using descriptive statistics and meta-analysis methods regarding the outcome after treatment of coronary in-stent restenosis was performed. The proportion of patients experiencing a major adverse cardiac event (MACE) as defined by death, myocardial infarction, and target lesion revascularization was the main outcome measure. A total of 1304 citations were identified. Among these, 28 studies (six different treatment modalities) including a total of 3012 patients met the inclusion criteria and were incorporated into this analysis. The estimated average probability of experiencing a major cardiac adverse event after treatment for in-stent restenosis with a follow-up period of 9±4 months was 30.0% (25.0–34.9%, 95% confidence interval) with strong evidence for heterogeneity between study specific results . The clinical outcome was not significantly different between treatment modalities. After adjustment for confounding factors (i.e. lesion length), however, patients undergoing intracoronary radiation showed an estimated advantage of 16.9% (–37.7±4.0%, 95% confidence interval) in MACE free survival, as compared to balloon angioplasty. The post-interventional diameter stenosis was the only independent predictor for the long-term outcome after treatment of in-stent restenosis.

Conclusions Treatment of in-stent restenosis is associated with an overall 30% rate of major adverse cardiac events. Currently, repeat angioplasty is the treatment option of choice, especially when a sufficient acute procedural result can be achieved. Intracoronary radiation should be considered in cases with therapy refractory forms of diffuse in-stent restenosis.

Key Words: Stent • Restenosis • Treatment • Outcome • Review • Meta-analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

A meta-analytical approach for the treatment of in-stent restenosis
N Mercado and P.W Serruys
EHJ 2003 24: 217-218. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
StrokeHome page
D. J. Fiorella, E. I. Levy, A. S. Turk, F. C. Albuquerque, G. L. Pride Jr, H. H. Woo, B. G. Welch, D. B. Niemann, P. D. Purdy, B. Aagaard-Kienitz, et al.
Target Lesion Revascularization After Wingspan: Assessment of Safety and Durability
Stroke, January 1, 2009; 40(1): 106 - 110.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Dibra, A. Kastrati, F. Alfonso, M. Seyfarth, M.-J. Perez-Vizcayno, J. Mehilli, and A. Schomig
Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials
J. Am. Coll. Cardiol., February 6, 2007; 49(5): 616 - 623.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. Mukherjee and D. J. Moliterno
Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement
JAMA, March 15, 2006; 295(11): 1307 - 1309.
[Full Text] [PDF]


Home page
HeartHome page
R Marcucci, D Brogi, F Sofi, C Giglioli, S Valente, A Alessandrello Liotta, M Lenti, A M Gori, D Prisco, R Abbate, et al.
PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting
Heart, March 1, 2006; 92(3): 377 - 381.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Alfonso, J. M. Auge, J. Zueco, A. Bethencourt, J. R. Lopez-Minguez, J. M. Hernandez, J. A. Bullones, I. Calvo, E. Esplugas, M. J. Perez-Vizcayno, et al.
Long-Term Results (Three to Five Years) of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Randomized Study
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 756 - 760.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F.-J. Neumann, W. Desmet, E. Grube, J. Brachmann, P. Presbitero, P. Rubartelli, A. Mugge, F. Di Pede, D. Fullgraf, W. Aengevaeren, et al.
Effectiveness and Safety of Sirolimus-Eluting Stents in the Treatment of Restenosis After Coronary Stent Placement
Circulation, April 26, 2005; 111(16): 2107 - 2111.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. Kastrati, J. Mehilli, N. von Beckerath, A. Dibra, J. Hausleiter, J. Pache, H. Schuhlen, C. Schmitt, J. Dirschinger, A. Schomig, et al.
Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial
JAMA, January 12, 2005; 293(2): 165 - 171.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. W Radke, S. Kobella, A. Kaiser, A. Franke, D. Schubert, E. Grube, P. Hanrath, and R. Hoffmann
Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary {beta}-radiation therapy
Eur. Heart J., June 1, 2004; 25(11): 920 - 925.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Eto, S. Biro, M. Miyata, H. Kaieda, H. Obata, T. Kihara, K. Orihara, and C. Tei
Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury
Cardiovasc Res, July 1, 2003; 59(1): 200 - 211.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
N Mercado and P.W Serruys
A meta-analytical approach for the treatment of in-stent restenosis
Eur. Heart J., February 1, 2003; 24(3): 217 - 218.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.